Ernexa Therapeutics Inc. (ERNA)
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $582.0K
- Net income
- -$14.1M
- Total assets
- $5.8M
- Market cap
- $9.2M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $9.3M
- Operating income
- -$9.3M
- Income tax
- -$45.0K
- Net income
- -$14.1M
- EPS (basic)
- $-2.24
- EPS (diluted)
- $-2.24
Balance sheet
- Total assets
- $5.8M
- Current assets
- $3.1M
- Total liabilities
- $3.4M
- Current liabilities
- $3.1M
- Shareholders’ equity
- $2.4M
Cash flow
- Operating cash flow
- -$7.0M
- Investing cash flow
- -$37.0K
- Financing cash flow
- $7.2M
- Net cash flow
- $155.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $9.2M
- EPS (diluted)
- $-2.24
- Shares outstanding
- 2.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 26, 2021
Ernexa Therapeutics Inc. (ERNA) Stock Price
- Reported a net loss of $14.1M in FY2024.
- Trading 94% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Ernexa Therapeutics Inc..
Write a review
News about Ernexa Therapeutics Inc.
News & sentiment via Polygon.io
Ernexa Therapeutics Inc.: frequently asked questions
Is Ernexa Therapeutics Inc. an American company?
Ernexa Therapeutics Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Ernexa Therapeutics Inc. headquartered?
Ernexa Therapeutics Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Ernexa Therapeutics Inc. publicly traded?
Yes — Ernexa Therapeutics Inc. is a publicly traded company. Its stock trades under the ticker symbol ERNA on the NASDAQ.
What does Ernexa Therapeutics Inc. do?
Ernexa Therapeutics Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
